Redwood City, CA – According to filings with the U.S. Securities and Exchange Commission, Biomea Fusion is raising $55,999,944.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Thomas Butler played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Biomea Fusion

Biomea Fusion, Inc. was formed in 2017 by a small group of biotech executives. We are dedicated to developing innovative medicines for patients. It is our goal to design and clinically develop patient friendly therapies with higher efficacy than the current standard of care. We are a precision oncology company developing novel small molecules that target aggressive forms of cancer. We leverage our in-house drug design and operational expertise to create novel small molecules against genetically defined forms of cancer. Our goal is to move these potentially breakthrough medicines swiftly through the development process and deliver highly impactful medicines for patients in need.

To learn more about Biomea Fusion, visit http://www.biomeafusion.com/

Contact:
Thomas Butler, Chief Executive Officer
650-980-9099
https://www.linkedin.com/in/thomasbutlerbiotech/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved